L
Letterio S. Politi
Researcher at Humanitas University
Publications - 130
Citations - 7137
Letterio S. Politi is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Transplantation. The author has an hindex of 35, co-authored 115 publications receiving 5882 citations. Previous affiliations of Letterio S. Politi include Sapienza University of Rome & University of Florence.
Papers
More filters
Journal ArticleDOI
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.
Michele De Palma,Mary Anna Venneri,Rossella Galli,Lucia Sergi Sergi,Letterio S. Politi,Maurilio Sampaolesi,Luigi Naldini +6 more
TL;DR: It is demonstrated that monocytes expressing the Tie2 receptor (Tie2-expressing monocytes [TEMs]) are a distinct hematopoietic lineage of proangiogenic cells that are selectively recruited to spontaneous and orthotopic tumors and promote angiogenesis in a paracrine manner.
Journal ArticleDOI
Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
Roberta Mazzieri,Ferdinando Pucci,Davide Moi,Erika Zonari,Anna Ranghetti,Alvise Berti,Letterio S. Politi,Bernhard Gentner,Jeffrey L. Brown,Luigi Naldini,Michele De Palma +10 more
TL;DR: Blocking angiopoietin-2 (ANG2), a TIE2 ligand and angiogenic factor expressed by activated endothelial cells (ECs), regresses the tumor vasculature and inhibits progression of late-stage, metastatic MMTV-PyMT mammary carcinomas and RIP1-Tag2 pancreatic insulinomas.
Journal ArticleDOI
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Andrés José Maria Ferreri,Kate Cwynarski,Elisa Jacobsen Pulczynski,Maurilio Ponzoni,Martina Deckert,Letterio S. Politi,Valter Torri,Christopher P. Fox,Paul La Rosée,Elisabeth Schorb,Achille Ambrosetti,Alexander Röth,Claire Hemmaway,Angela Ferrari,Kim Linton,Roberta Rudà,Mascha Binder,Tobias Pukrop,Monica Balzarotti,Alberto Fabbri,Peter Johnson,Jette Sønderskov Gørløv,Georg Hess,Jens Panse,Francesco Pisani,Alessandra Tucci,Stephan Stilgenbauer,Bernd Hertenstein,Ulrich Keller,Stefan W. Krause,Alessandro Levis,Hans J. Schmoll,Franco Cavalli,Jürgen Finke,Michele Reni,Emanuele Zucca,Gerald Illerhaus +36 more
TL;DR: The IELSG32 trial provides a high level of evidence supporting the use of MATRix combination as the new standard chemoimmunotherapy for patients aged up to 70 years with newly diagnosed primary CNS lymphoma and as the control group for future randomised trials.
Journal ArticleDOI
Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia.
Journal ArticleDOI
Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis
Michele De Palma,Roberta Mazzieri,Letterio S. Politi,Ferdinando Pucci,Erika Zonari,Giovanni Sitia,Stefania Mazzoleni,Davide Moi,Mary Anna Venneri,Stefano Indraccolo,Andrea Falini,Luca G. Guidotti,Rossella Galli,Luigi Naldini +13 more
TL;DR: This work exploited the tumor-homing ability of proangiogenic Tie2-expressing monocytes (TEMs) to deliver IFN-alpha to tumors and obtained significant antitumor responses and near complete abrogation of metastasis.